Monte Rosa Therapeutics, Inc. Research and Development Expense
Monte Rosa Therapeutics, Inc. (GLUE) reported Research and Development Expense of $47.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $47.96M, a 56.47% increase year-over-year.
- Monte Rosa Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $44.07M, a 36.90% increase year-over-year.
- Monte Rosa Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $41.98M, a 8.01% increase year-over-year.
- Monte Rosa Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $36.68M, a 32.81% increase year-over-year.
- Monte Rosa Therapeutics, Inc. research and development expense for fiscal 2025 was $141.50M, a 16.40% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. research and development expense for fiscal 2024 was $121.56M, a 9.25% increase from fiscal 2023.
- Monte Rosa Therapeutics, Inc. research and development expense for fiscal 2023 was $111.27M, a 30.81% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. research and development expense for fiscal 2022 was $85.06M, a 48.83% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.96M 10-Q · filed 2026-08-06 | $92.03M 10-Q · filed 2026-08-06 | $134.01M derived: sum of 3 quarters · filed 2026-08-06 | $170.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $44.07M 10-Q · filed 2026-05-07 | $86.05M derived: sum of 2 quarters · filed 2026-05-07 | $122.73M derived: sum of 3 quarters · filed 2026-05-07 | $153.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $41.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $78.66M derived: sum of 2 quarters · filed 2026-03-17 | $109.31M derived: sum of 3 quarters · filed 2026-08-06 | $141.50M 10-K · filed 2026-03-17 |
| 2025-09-30 | $36.68M 10-Q · filed 2025-11-06 | $67.33M derived: sum of 2 quarters · filed 2026-08-06 | $99.52M 10-Q · filed 2025-11-06 | $138.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $30.65M 10-Q · filed 2026-08-06 | $62.84M 10-Q · filed 2026-08-06 | $101.71M derived: sum of 3 quarters · filed 2026-08-06 | $129.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $32.19M 10-Q · filed 2026-05-07 | $71.06M derived: sum of 2 quarters · filed 2026-05-07 | $98.67M derived: sum of 3 quarters · filed 2026-05-07 | $126.73M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $38.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $66.48M derived: sum of 2 quarters · filed 2026-03-17 | $94.54M derived: sum of 3 quarters · filed 2026-03-17 | $121.56M 10-K · filed 2026-03-17 |
| 2024-09-30 | $27.62M 10-Q · filed 2025-11-06 | $55.67M derived: sum of 2 quarters · filed 2025-11-06 | $82.70M 10-Q · filed 2025-11-06 | $109.83M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $28.05M 10-Q · filed 2025-08-07 | $55.08M 10-Q · filed 2025-08-07 | $82.22M derived: sum of 3 quarters · filed 2025-08-07 | $110.52M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $27.03M 10-Q · filed 2025-05-08 | $54.16M derived: sum of 2 quarters · filed 2025-05-08 | $82.47M derived: sum of 3 quarters · filed 2025-05-08 | $111.54M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $27.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $55.44M derived: sum of 2 quarters · filed 2025-03-20 | $84.52M derived: sum of 3 quarters · filed 2025-03-20 | $111.27M 10-K · filed 2025-03-20 |
| 2023-09-30 | $28.31M 10-Q · filed 2024-11-07 | $57.38M derived: sum of 2 quarters · filed 2024-11-07 | $84.14M 10-Q · filed 2024-11-07 | $109.00M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $29.08M 10-Q · filed 2024-08-08 | $55.83M 10-Q · filed 2024-08-08 | $80.70M derived: sum of 3 quarters · filed 2024-08-08 | $102.04M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $26.75M 10-Q · filed 2024-05-09 | $51.62M derived: sum of 2 quarters · filed 2024-05-09 | $72.97M derived: sum of 3 quarters · filed 2024-05-09 | $93.90M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $24.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $46.21M derived: sum of 2 quarters · filed 2024-03-14 | $67.15M derived: sum of 3 quarters · filed 2024-03-14 | $85.06M 10-K · filed 2024-03-14 |
| 2022-09-30 | $21.34M 10-Q · filed 2023-11-09 | $42.28M derived: sum of 2 quarters · filed 2023-11-09 | $60.19M 10-Q · filed 2023-11-09 | $78.32M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $20.94M 10-Q · filed 2023-08-10 | $38.85M 10-Q · filed 2023-08-10 | $56.98M derived: sum of 3 quarters · filed 2023-08-10 | $72.10M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $17.91M 10-Q · filed 2023-05-11 | $36.05M derived: sum of 2 quarters · filed 2023-05-11 | $51.16M derived: sum of 3 quarters · filed 2023-05-11 | $65.80M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $18.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $33.24M derived: sum of 2 quarters · filed 2023-03-16 | $47.88M derived: sum of 3 quarters · filed 2023-03-16 | $57.16M 10-K · filed 2023-03-16 |
| 2021-09-30 | $15.12M 10-Q · filed 2022-11-10 | $29.75M derived: sum of 2 quarters · filed 2022-11-10 | $39.02M 10-Q · filed 2022-11-10 | $48.89M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $14.64M 10-Q · filed 2022-08-11 | $23.91M 10-Q · filed 2022-08-11 | $33.77M derived: sum of 3 quarters · filed 2022-08-11 | $39.24M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $9.27M 10-Q · filed 2022-05-11 | $19.14M derived: sum of 2 quarters · filed 2022-05-11 | $24.61M derived: sum of 3 quarters · filed 2022-05-11 | $29.46M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $9.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $15.34M derived: sum of 2 quarters · filed 2022-03-29 | $20.19M derived: sum of 3 quarters · filed 2022-03-29 | $24.00M 10-K · filed 2022-03-29 |
| 2020-09-30 | $5.47M 10-Q · filed 2021-11-10 | $10.33M derived: sum of 2 quarters · filed 2021-11-10 | $14.14M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $4.86M 10-Q · filed 2021-08-12 | $8.67M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |